Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Homology Medicines's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FIXX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: FIXX's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: FIXX underperformed the US Biotechs industry which returned 19.7% over the past year.
Return vs Market: FIXX underperformed the US Market which returned 50.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Homology Medicines's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHomology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
2 months ago | Simply Wall StAre Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?
3 months ago | Simply Wall StHomology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year
Is Homology Medicines undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FIXX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FIXX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FIXX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FIXX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FIXX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FIXX is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.3x).
How is Homology Medicines forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FIXX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FIXX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FIXX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FIXX's revenue (61.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: FIXX's revenue (61.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FIXX's Return on Equity is forecast to be high in 3 years time
How has Homology Medicines performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FIXX is currently unprofitable.
Growing Profit Margin: FIXX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FIXX is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare FIXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FIXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).
Return on Equity
High ROE: FIXX has a negative Return on Equity (-47.02%), as it is currently unprofitable.
How is Homology Medicines's financial position?
Financial Position Analysis
Short Term Liabilities: FIXX's short term assets ($191.7M) exceed its short term liabilities ($17.8M).
Long Term Liabilities: FIXX's short term assets ($191.7M) exceed its long term liabilities ($16.1M).
Debt to Equity History and Analysis
Debt Level: FIXX is debt free.
Reducing Debt: FIXX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FIXX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FIXX has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 48% each year.
What is Homology Medicines's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FIXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FIXX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FIXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FIXX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FIXX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Arthur Tzianabos (57 yo)
Dr. Arthur O. Tzianabos, Ph.D., has been the Chief Executive Officer, President and Director of Homology Medicines, Inc. since April 2016. Dr. Tzianabos serves as a Director of Alliance for Regenerative Me...
CEO Compensation Analysis
Compensation vs Market: Arthur's total compensation ($USD885.96K) is below average for companies of similar size in the US market ($USD1.74M).
Compensation vs Earnings: Arthur's compensation has been consistent with company performance over the past year.
Experienced Management: FIXX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: FIXX's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.
Homology Medicines, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Homology Medicines, Inc.
- Ticker: FIXX
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$367.036m
- Shares outstanding: 57.08m
- Website: https://www.homologymedicines.com
Number of Employees
- Homology Medicines, Inc.
- One Patriots Park
- United States
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopo...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 22:51|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.